Table 1.
Participant Characteristics (Mean±S.E.M)
| SN Controls (n=31) |
HIV+ Participants (n=35) |
P-value from T-test or χ2 |
|
|---|---|---|---|
| Age (years) | 50.2 ± 2 | 54.1 ± 1.6 | 0.12 |
| Number of Men (%) | 29 (93.6) | 32 (91.4) | 0.75 |
| Race (% Asian/White/ American Indian/ Pacific Islander/ Black or African American/ More than one race) | 22.6/ 48.4/ 0/ 22.6/ 0/ 6.5 | 17.1/ 37.1/ 5.7/ 14.3/ 8.6/ 17.1 | 0.2 |
| Education (years) | 15.2 ± 0.5 | 14.3 ± 0.4 | 0.16 |
| Index of Social Position (ISP) | 38.3 ± 2.9 | 38 ± 2.8 | 0.94 |
| # using pain medication* (%) | 5 (16) | 7 (20) | 0.17 |
| CES-D score | 9.7 ± 2.1 | 11.1 ± 1.8 | 0.68 |
| # with Distal Neuropathy** (%) | 8 (25.8) | 19 (55.9) | 0.01 |
| # with headaches** (%) | 5 (16.1) | 3 (8.8) | 0.4 |
| CD4 Count (#/mm3) | 584.4 ± 52.8 | ||
| Viral Load (copies/mL) | 83 ± 39.7 | ||
| log Viral Load (log copies/mL) | 1.46 ± 0.08 | ||
| Duration of HIV Diagnosis (months) | 193.3± 17.3 | ||
| # on Antiretroviral Treatment (%) | 34 (97.1%) |
*
Pain medications reported include opioids (oxycodone, hydrocodone, 7/12,,58%), nonsteriodal anti-inflammatory drugs (NSAIDS, aspirin, ibuprofen, naproxen, 7/12, 58%), Tramadol (2/12, 17%), and muscle relaxant (carisoprodol, 1/12, 8%)
**
N=65. One HIV subject had missing data on headache and distal neuropathy.